Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 7

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
 Net cash provided by financing activities4,561 6,397 Effect of exchange rates changes on cash, cash equivalents, and restricted cash441 105 Net increase in cash, cash equivalents, and restricted cash88,642 38,875 Cash, cash equivalents, and restricted cash at beginning of period344,067 359,284 Cash, cash equivalents, and restricted cash at end of period$432,709 $398,159 Supplemental disclosures of cash flow information:Cash paid for taxes$1,935 $4,863 Noncash investing and financing activities:Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities$135 $954 Right-of-use assets obtained in exchange for new operating lease liabilities$11,362 $— Common stock issued for acquisition of assets$13,541 $— 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

o

1.    Description of Business and Basis of Presentation

Organization and Description of Business10x Genomics, Inc. (the “Company”) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated research solutions include the Company’s Chromium instruments and the Company's Visium CytAssist and Xenium Analyzer, which the Company refers to as “Spatial instruments,” and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for the Company’s Chromium, Visium and Xenium solutions, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company was incorporated in the state of Delaware in July 2012 and began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe, Oceania and North America.Basis of PresentationThe accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheet at December 31, 2024 has been derived from the aud